HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0

CUSIP: 40637HAD1

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Debt / NOTE 0.250% 3/0
Market price (% of par)
83.28%
Total 13F principal
$794,335,832
Principal change
+$24,332,877
Total reported market value
$662,252,900
Number of holders
67
Value change
+$19,666,070
Number of buys
29
Number of sells
22

Quarterly Holders Quick Answers

What is CUSIP 40637HAD1?
CUSIP 40637HAD1 identifies 40637HAD1 - HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q2 2023

As of 30 Jun 2023, HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by 67 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $794,335,832 in principal (par value) of the bond. The largest 10 bondholders included Voya Investment Management LLC, CAMDEN ASSET MANAGEMENT L P /CA, Invesco Ltd., Wellesley Asset Management, Linden Advisors LP, DAVIDSON KEMPNER CAPITAL MANAGEMENT LP, CITIGROUP INC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, AVIVA PLC, and AMERIPRISE FINANCIAL INC. This page lists 67 institutional bondholders reporting positions for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.